Anavex Life Sciences Corp. (AVXL) |
|
8.72 0.04 (0.46%)
|
03-24 16:00 |
|
Open: |
8.6 |
Pre. Close: |
8.68 |
|
High:
|
8.79 |
Low:
|
8.42 |
|
Volume:
|
993,519 |
Market Cap:
|
680(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:13 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 11.37  One year: 12.35 |
| Support: |
Support1: 8.38 Support2: 6.97 |
| Resistance: |
Resistance1: 9.73 Resistance2: 10.57 |
| Pivot: |
9.33 |
| Moving Average: |
MA(5): 8.85 MA(20): 9.42
MA(100): 10.23 MA(250): 10.22 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 11.5 %D(3): 17.2 |
| RSI: |
RSI(14): 36.5  |
| 52-week: |
High: 15.23 Low: 7.13 |
| Average Vol(K): |
3-Month: 1,186 (K) 10-Days: 1,319 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AVXL ] has closed above bottom band by 15.5%. Bollinger Bands are 35.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.8 - 8.85 |
8.85 - 8.89 |
|
Low:
|
8.32 - 8.37 |
8.37 - 8.41 |
|
Close:
|
8.64 - 8.72 |
8.72 - 8.79 |
|
Company Description |
|
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. |
Headline News |
Sun, 19 Mar 2023
Validea's Top Ten Healthcare Stocks Based On Warren Buffett - 3/19 ... - Nasdaq
Thu, 16 Mar 2023
Buy Anavex For Its Likely Positive Alzheimer's Disease Data ... - Seeking Alpha
Wed, 15 Mar 2023
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value - Nasdaq
Wed, 15 Mar 2023
13414 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL ... - MarketBeat
Mon, 13 Mar 2023
Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome - Nasdaq
Thu, 09 Mar 2023
Anavex Life Sciences Appoints Former FDA Lead Neurology ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
78 (M) |
| Shares Float |
76 (M) |
|
% Held by Insiders
|
3 (%) |
|
% Held by Institutions
|
35.2 (%) |
|
Shares Short
|
16,320 (K) |
|
Shares Short P.Month
|
16,720 (K) |
Stock Financials |
|
EPS
|
-0.67 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.73 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-21.1 |
|
Return on Equity (ttm)
|
-35.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-27 (M) |
|
Levered Free Cash Flow
|
-9 (M) |
Stock Valuations |
|
PE Ratio
|
-13.22 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
5.04 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-25.65 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
